Meridian Bioscience Stock News

CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board

Meridian Bioscience, Inc. (NASDAQ:VIVO)s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $21.40, but opened at $20.70. Meridian Bioscience shares last traded at $20.01, with a volume of 1,177 shares traded. A number of brokerages recently issued reports on VIVO. HC Wainwright upped their price objective on []

Related Stocks: VIVO ,

Zacks Investment Research downgraded shares of Meridian Bioscience (NASDAQ:VIVO) from a hold rating to a sell rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and []

Goldman Sachs Group Inc. cut its holdings in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 42.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 216,361 shares of the companys stock after selling 159,765 shares during the quarter. Goldman Sachs Group Inc.s holdings in Meridian Bioscience were worth $4,799,000 as of its most recent []

CINCINNATI, Nov. 18, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 st and 2 nd , 2021.

AQR Capital Management LLC decreased its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 34.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,357 shares of the company’s stock after selling 29,569 shares during the period. AQR Capital […]

Meridian Bioscience (NASDAQ:VIVO) updated its FY 2022 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $0.980-$1.080 for the period, compared to the Thomson Reuters consensus estimate of $1.070. The company issued revenue guidance of $285 million-$300 million, compared to the consensus revenue estimate of $283.27 million. Several research firms recently []

Meridian Bioscience (NASDAQ:VIVO) issued its earnings results on Friday. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of $0.21 by $0.02, MarketWatch Earnings reports. Meridian Bioscience had a net margin of 23.29% and a return on equity of 24.58%. During the same quarter last year, the company []

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q4 2021 Earnings Conference Call - Earnings Call Transcript

Meridian Bioscience Inc (NASDAQ: VIVO) posted Q4 sales of $76.2 million, up 19% Y/Y, beating the consensus of $68.40 million. Diagnostics segment net revenues increased 15% Y/Y to $34.3 million, led

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CINCINNATI, Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report fourth quarte

CINCINNATI, Oct. 7, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch